Protecting intellectual property associated with health technology trials – another barrier to multi-centre trials? by Ross, Sue et al.
ORAL PRESENTATION Open Access
Protecting intellectual property associated with
health technology trials – another barrier to
multi-centre trials?
Sue Ross
1*, Laura Magee
2, Stephen Wood
1
From Clinical Trials Methodology Conference 2011
Bristol, UK. 4-5 October 2011
Objective
To examine the approaches to protection of intellectual
property in multi-centre trials currently being conducted
in Canada.
Methods
Two ongoing international multicentre perinatal trials,
both funded by the Canadian Institutes of Health
Research, were selected for study on the basis of their
contrasting approaches to protecting intellectual prop-
erty. These approaches were examined in detail to
understand their motivation, and to estimate the impact
of these approaches on centre recruitment.
Results
CHIPS (Control of Hypertension in Pregnancy Study,
ISRCTN71416914) – is recruiting 1028 pregnant
women in 14 countries. Women with hypertension are
randomised to tight or less tight control of hyperten-
sion. Primary outcome: composite of pregnancy loss/
neonatal intensive care.
Intellectual property is safeguarded by publishing the
protocol online [1]. Positive consequences: possible/
actual sites have easy access to full study design; poten-
tial for open discussion between collaborators; study
investigators will be held to high standards of reporting.
Negative consequences: details are available with poten-
tial for plagiarism.
FACT (Folic Acid Clinical Trial, ISRCTN23781770)
– is recruiting 3656 pregnant women in 4 countries.
Pregnant women are randomised to receive either 4 mg
folic acid or placebo daily. Primary outcome: develop-
ment of pre-eclampsia.
Intellectual property is safeguarded by requiring local
investigators/institutions to sign non-disclosure agree-
ments (NDAs) before the full protocol is provided. Posi-
tive consequences: details of the study not available
unless legal agreement is signed. Negative consequences:
may restrict academic openness; provide additional bar-
riers to site recruitment; investigators may present
selected results.
Conclusions
The two trials illustrate contrasting approaches to pro-
tecting intellectual property associated with study
design. This issue is becoming more important for aca-
demic institutions whose reputations and wealth are
influenced by ownership and management of the intel-
lectual property generated by faculty members. Some
institutions prefer to manage risk using legal measures.
In the case of trials, institutions protect their intellectual
property by introducing NDAs into the sub-site agree-
ment process.
NDAs between the lead institution and sub-sites may
represent a legally responsible approach. Unfortunately
there are potential disadvantages: adding an extra legal
step into sub-site recruitment will make this process
more difficult; this step may reduce academic openness
and collegiality; and restricting the availability of the
protocol could allow investigators to present selected
results.
The use of non-disclosure agreements is an increasing
trend in Canada. This trend will impact on the work of
clinical trialists, perhaps making site recruitment even
more difficult.
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